KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Thermo Fisher Scientific (TMO) Total Debt (2016 - 2025)

Thermo Fisher Scientific's Total Debt history spans 17 years, with the latest figure at $39.4 billion for Q4 2025.

  • For the quarter ending Q4 2025, Total Debt rose 25.93% year-over-year to $39.4 billion, compared with a TTM value of $39.4 billion through Dec 2025, up 25.93%, and an annual FY2025 reading of $39.4 billion, up 25.93% over the prior year.
  • Total Debt for Q4 2025 was $39.4 billion at Thermo Fisher Scientific, up from $35.7 billion in the prior quarter.
  • The five-year high for Total Debt was $39.4 billion in Q4 2025, with the low at $18.6 billion in Q2 2021.
  • Average Total Debt over 5 years is $32.1 billion, with a median of $34.7 billion recorded in 2021.
  • Year-over-year, Total Debt fell 11.9% in 2021 and then surged 78.36% in 2022.
  • Tracing TMO's Total Debt over 5 years: stood at $34.9 billion in 2021, then fell by 1.1% to $34.5 billion in 2022, then rose by 1.24% to $34.9 billion in 2023, then decreased by 10.43% to $31.3 billion in 2024, then increased by 25.93% to $39.4 billion in 2025.
  • Per Business Quant, the three most recent readings for TMO's Total Debt are $39.4 billion (Q4 2025), $35.7 billion (Q3 2025), and $35.2 billion (Q2 2025).